Novo Nordisk Mulls Expanding Direct-to-consumer Business

07:04 AM EDT, 09/22/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) is considering expanding its direct-to-consumer pharmaceuticals business into areas including hair loss, addiction and menopause, Bloomberg News reported Tuesday, citing Chief Scientific Officer Martin Lange. At a Bloomberg roundtable, Lange said the drugmaker could utilize its scientific expertise to develop therapies for such conditions. The company's move into hair loss could, however, take time as it is not one of the eight conditions for which treatments are expected to be in mid-stage trials by late 2026 or early 2027, Lange added. Novo is also looking at new potential treatments for heart disease, liver and blood disorders and will further eye bolt-on deals and speed up its internal drug pipeline.